• Beware! Hypertension is getting closer to you.
    17

    /May 2022

    Beware! Hypertension is getting closer to you.
    This year is the 18th International Hypertension Day, with the theme Measure Your Blood Pressure Accurately, Control It, Live Longer. The prerequisite for effective control to extend your life is to know about hypertension. So what do you need to know? Let's take a look. What is hypertension? Hypertension (hypertension) is a clinical syndrome characterised by increased arterial blood pressure in the circulation (systolic blood pressure ≥ 130 mmHg and diastolic blood pressure ≥ 80 mmHg), which may be accompanied by functional or organic damage to the heart, brain, kidneys and other organs. 5-10% of hypertension is secondary hypertension, caused by endocrine, renal or vascular diseases. About 90% of hypertension is essential hypertension of unknown aetiology. The prevalence and dangers of hypertension Hypertension is the most common disease of the cardiovascular system in humans. It is a significant risk factor for coronary heart disease, myocardial infarction, stroke, renal insufficiency, and even death, which causes high rates of disability and death and a severe drain on medical and social resources and a heavy burden on families and the nation. Hypertension is a preventable and controllable disease. Reducing blood pressure levels in patients with hypertension can significantly reduce stroke and cardiac events, greatly improve patients' quality of life, and effectively reduce the burden of disease. Hypertension is a disease that is closely related to lifestyle. With urbanisation and mechanisation, the number of hypertensive patients will only increase. Therefore, when an occasional check-up reveals an increase in blood pressure, or symptoms such as dizziness, headache, blurred vision, tinnitus, insomnia, weakness, tightness in the neck, palpitations and lack of concentration, it is advisable to take further diagnostic measures to help determine the course of the disease. To help control hypertension 1. Rational diet (1) low salt diet: can lower systolic blood pressure by 2-8 mmHg; (2) low-fat diet; (3) low-calorie diet. 2. Moderate exercise Gradual, moderate and regular exercise can reduce systolic blood pressure by 4-9 mmHg. (1) Form of exercise: aerobic exercise is advocated; (2)Time of exercise: an exercise in the evening rather than in the morning is appropriate for hypertensive patients because blood pressure fluctuates in the morning, and exercise in the morning can cause a sharp rise in blood pressure and trigger cardiovascular and cerebrovascular events. 3. Weight control BMI should be controlled to below 25 kg/m2. 4. Quit smoking and limit alcohol (1) Smoking increases the risk of heart disease by 2-4 times; (2) limiting alcohol can lower systolic blood pressure by 2-4 mmHg, with different daily limits for different types of alcohol. 5. Live a regular life and have a happy spirit
    View More
  • Managing COVID-19 and influenza during flu season
    13

    /May 2022

    Managing COVID-19 and influenza during flu season
    Flu and COVID-19 Influenza, or the flu, and COVID-19 are both respiratory illnesses caused by different viruses. Flu is caused by influenza viruses (Type A and B are two main types of influenza viruses), while COVID-19 comes from the novel coronavirus, known as SARS-CoV-2. Both viruses can be spread between people in close contact through droplets that come from coughing, sneezing and talking. Flu and COVID-19 Similarities Although COVID-19 spreads more easily and remains contagious for longer periods of time than influenza, it is hard to tell the difference between them due to the similarity in symptoms. Therefore, early and widespread reliable testing is more important than ever to help healthcare professionals differentiate between influenza and COVID-19. As a trusted in vitro diagnostic national enterprise in China, Getein has been at the forefront of developing a comprehensive combo test for COVID-19 and influenza, which enables healthcare providers to rapidly and effectively differentiate between the SARS-CoV-2 and influenza A/B viruses, make informed treatment decisions and improve patient outcomes. One Step Test for FluA/FluB/SARS-CoV-2 Antigen (Colloidal Gold) Getein will continuously pay close attention to global health issues and needs in real time, to help combat the pandemic, reduce the burden on healthcare systems and optimize patient management. Reference: Centers for Disease Control and Prevention. [Internet; cited January 2021]. The difference between influenza and COVID-19. Available from: https://www.cdc.gov/flu/symptoms/flu-vs-covid19. htm
    View More
  • Happy Mother's Day-Getein Protect the Health of Mothers
    08

    /May 2022

    Happy Mother's Day-Getein Protect the Health of Mothers
    Happy Mother's Day-Getein Protect the Health of Mothers A mother's love is the most selfless and the greatest love of all. The 109th Mother's Day falls on May 8, 2022. Getein Biotech wishes mothers around the world a happy holiday! Focuses on Women's Health, Getein Always Getein has always placed a high priority on motherhood and women's health. Getein Biotech launches a wide range of testing items for mothers and mothers-to-be, including different test biomarkers and testing analyzers for fertility, to protect the reproductive and physical health of global women. “Test Guide” of Getein for Mothers Getein recommends testing seven hormones which play an extremely important role in female reproductive health. Follicle-Stimulating Hormone (FSH) and luteinizing Hormone (LH) are two sex hormones secreted by the pituitary gland, and their levels are higher in blood when polycystic ovary syndrome (PCOS) exists, a condition with sporadic ovulation and polycystic ovaries. On the other hand, Estrogen (E2) and Progesterone (Prog) from the ovaries always relate to the infertility, which should be tested for women preparing for pregnancy. Prolactin (PRL) and Testosterone (T) also have the similar function of infertility diagnosis. On the contrary, HCG+β can indicate the probability of fertility with the change in concentration and help trophoblastic tumor diagnosis. MAGICL6000-A New Generation of Chemiluminescence Analyzer for Hormone Testing MAGICL6000 Chemiluminescence Immunoassay Analyzer is an innovative immunochemistry solution, which is a fully automatic system with small size and high throughput. Getein provides seven sex hormone testing items on MAGIAL6000 to comprehensively cover the female reproduction diagnosis and protect the health of mothers and mothers-to-be. Mother's love and health have no boundaries. Getein will continue to focus on motherhood and women's health issues to guard the reproductive health of women worldwide.
    View More
  • Didn't expect it——Fighting malaria isn't that difficult!
    25

    /Apr 2022

    Didn't expect it——Fighting malaria isn't that difficult!
    What is malaria? Mosquitoes top the list of the 15 most deadly animals to humans, harming more people each year than all the other animals combined. As well as sucking human blood, mosquitoes spread a variety of diseases. Malaria is an insect-borne disease caused by exposure to Plasmodium vivax blood after a mosquito bite. How severe is malaria? On 27 October 2017, the World Health Organization's International Agency for Research on Cancer published a preliminary collation of references to the list of carcinogens, with malaria (caused by Plasmodium falciparum infection in highly endemic areas) in the list of Group 2A carcinogens. (1) The global prevalence of malaria remains high to date, with approximately 40% of the world's population living in malaria-endemic areas. Malaria remains the most severe disease on the African continent, with around 500 million people living in malaria-endemic regions and about 100 million people worldwide having clinical symptoms of malaria each year, 90% of whom are on the African continent, with over 2 million deaths from malaria each year. Southeastern and Central Asia are also areas where malaria is rampant. Malaria is still endemic in Central and South America (2). Meanwhile, the burden of malaria in some countries in Africa is on the rise, influenced by factors such as the COVID-19 epidemic and a reduction in the proportion of international funding. World Malaria Map China's experience in the fight against malaria Over the past few decades, China has worked tirelessly to eliminate malaria. Removing the transmission cycle between the malaria-transmitting Anopheles mosquito and humans, developing anti-malarial drugs, and developing new detection methods (3) have seen the number of malaria infections in China drop from 30 million to 0. Many people may not be aware of the magnitude of this achievement, as malaria hasn't been heard of around for a long time. But if you look around the world or go back 70 years, malaria is a familiar evil that has stayed with us. From familiar to unfamiliar, from 30,000,000 to 0, it was a triumph of the national effort. On 29 June 2021, the World Health Organization (WHO) officially declared China utterly free of malaria, becoming the 40th country in the world to achieve so (4). In a statement, Pedro Alonso, director of the WHO's Global Malaria Programme, said that China's ability to think out of the box had served the country well in its response to malaria. National malaria incidence, 1950-2019, Source: China CDC Dynamics Bringing China's experience of defeating malaria to the world The world is one, and no country can stay out of the way when disease strikes. China's success has not only benefited the Chinese people, but the experience of fighting malaria is increasingly appearing in the world. Long-lasting insecticide-impregnated nets originated in China and are produced for use around the world Photo credit: WHO China helps Papua New Guinea build experimental base for malaria te...
    View More
  • 【Getein Daily】Getein Rapid Antigen Test Kit Has Been Re-accredited by HKBMIA
    23

    /Mar 2022

    【Getein Daily】Getein Rapid Antigen Test Kit Has Been Re-accredited by HKBMIA
    The launch of "Comparison of the Efficacy of 24 Brands of Rapid Antigen Test Reagents", organized by the Hong Kong Biomedical Innotech Association (HKBMIA), has drawn to a close recently. Many experts in biological research and testing technology from Hong Kong participated in this efficacy comparison. Firstly, these experts aimed to analyze the test agents based on publicly available information, i.e. to check whether they belonged to an authoritative approved list, e.g. whether they belonged to the HKSAR government approved, NMPA approved, FDA approved, CE certificate. Secondly, the independent German PEI study results and the manufacturer's clinical performance data were consulted. In addition to this, the experts also compared the 24 reagents included in the selection by combining many indicators such as sensitivity, specificity, stability and user-friendliness. The comparison results showed that theRapid Antigen detection reagentsfrom our company - Getein were rated in the top 4 of the overall list and the top 9 of the comparative study of the tests. During the COVID-19 pandemic, the safety and security of individuals is a top priority in the current outbreak. Getein has been continuously expanding and updating the range of COVID-19 reagents and enhancing its research and development capabilities to protect people's health. As one of the leaders in the field ofin vitrodiagnostics in China, Getein not only provides innovative testing products and quality services to medical institutions and patients but also shows the public the rising role of Chinese enterprises in the fight against the pandemic with its hardcore, high efficiency, innovation and commitment. It has also shown the world the tremendous power of Chinese companies in responding to major public health events. The Hong Kong SAR Government Department of Health Center for Health Protection announced on the afternoon of March 16 - as midnight of that day, 14,454 new patients of novel coronavirus pneumonia confirmed by Nucleic Acid Test were diagnosed in Hong Kong; 14,818 new cases were added to the Rapid Antigen Test positive reporting platform; a total of 29,272 new cases were confirmed throughout the day. From this data, it is easy to see that the Rapid Antigen Test accounted for almost half of the confirmed cases. In the early fight against the pandemic in Hong Kong, there was often a shortage oftest kitsand insufficient test capacity. The fifth wave of the outbreak in Hong Kong is raging and has plagued many people, and Getein is no exception.With 20 years of experience in the industry, Getein quickly integrated resources and increased production capacity and sent large quantities of antigen self-testing supplies to Hong Kong urgently to protect our compatriots in Hong Kong and bring great convenience to the detection and treatment of novel coronavirus pneumonia. The product that Getein were evaluated in Hong Kong is theOne Step Test for SARS-CoV-2 Antigen (Colloidal Gold), which ...
    View More
  • Getein Biotech Fights COVID-19 Together with Hong Kong!
    08

    /Mar 2022

    Getein Biotech Fights COVID-19 Together with Hong Kong!
    The number of COVID-19 infections in Hong Kong has been surging in the 5th wave of the outbreak, with 10785 additional confirmed cases and 4721 additional asymptomatic cases as of March 6, according to the updated statistics from the Centre for Health Protection (CHP) of the Department of Health (DH) of Hong Kong. Immediate Response, Effective Collaboration Knowing the fact that nucleic acid testing materials were insufficient in Hong Kong, Getein responded quickly and increased the production capacity of antigen test kits by equipment upgrade, process optimization, technology innovation and resources integration, to ensure sufficient supplies to deliver to Hong Kong and help fight the outbreak. In order to guarantee the timely arrival of anti-epidemic supplies to Hong Kong, Nanjing Customs has taken measures to ship the anti-epidemic materials at the first time by early declaration and rapid inspection. At present, the first batch of COVID-19 antigen testing kits has been delivered to Hong Kong to meet the most urgent needs of Hong Kong citizens and health-care workers. Easy and Fast Testing The product that Getein delivered to Hong Kong is One Step Test for SARS-CoV-2 Antigen (Colloidal Gold), which is very easy and fast to operate. No testing equipment is required. Individuals could perform the test by collecting nasal swab sample themselves. The sampling process is simple and comfortable and the test results can be obtained in just 10-15 minutes. The convenient operation allows this test to be widely used in many scenarios such as home, workplace, school, etc. Multiple Certifications, Quality Guaranteed By now, Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold)(for self-test) has received CE certification and been listed in the EU common list. Besides, the test kit has been validated and approved by Thailand FDA, Malaysia MDA, the Philippines FDA and the UK CTDA. In addition, Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) has also passed the PEI evaluation and the phase 3a validation of British DHSC. the phase 3a validation of British DHSC. At this globally difficult time, Getein Biotech Inc. will continuously focus the pandemic and contribute itself to the prevention and control of the COVID-19 pandemic, to promptly support the resumption of the global work & production as well as the early return of people’s normal life.
    View More
  • Getein SARS-CoV-2 Antigen Self-Test Certified by CTDA of the UK
    01

    /Mar 2022

    Getein SARS-CoV-2 Antigen Self-Test Certified by CTDA of the UK
    BREAKING NEWS On Feb 15th, 2022, Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) was approved by Coronavirus Test Device Approvals (CTDA) of Department of Health and Social Care (DHSC) in the UK. This is the FIRST COVID-19 antigen self-test kit (nasal swab) approved by CTDA, which means that Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) is now permitted to enter the UK market. *MHRA is an executive government agency under the Ministry of Health of the UK, which ensures the safety and effectiveness of medicines and medical devices. Link: https://www.gov.uk/government/publications/covid-19-test-validation-approved-products WHO Recommendation According to WHO, as a diagnostic method of SARS-CoV-2 infection, Ag-RDT (Antigen-detecting Rapid Diagnostic Test) plays an important role in patient management, public health prevention and control, and COVID-19 monitoring during this pandemic, especially in areas where clinical diagnosis, treatment and prevention and control of COVID-19 are difficult due to lack of nucleic acid detection ability. In addition, Ag-RDT can offer a faster and less expensive way to diagnose active SARS-CoV-2 infection than nucleic acid amplification tests (NAATs). Getein Antigen Self-Test One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) is intended for the qualitative detection of SARS-CoV-2 antigens in human nasal swab samples. This test is suitable for medical laypersons as a self-test at home or at work. The test kit is easy and fast to operate without detection equipment. Users can collect nasal swabs by themselves at home, and the detection results can be obtained in only 10-15 minutes, which is very convenient for individuals and families to have a quick detection. Multiple Certifications, Quality Guaranteed In addition to the UK CTDA, Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) is also CE marked and listed in the EU common list. Besides, the test kit has also passed the PEI evaluation and the phase 3a validation of British DHSC. What’s more, Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) is validated and approved by Thailand FDA, Malaysia MDA and Philippines FDA. These certificates and validations provide strong proof for the high quality and good accuracy of the test kit. Just as a performance evaluation conducted by Centralne Laboratorium Kliniczine Centrum Kliniczne (Commissioned by Getein Biotech, Inc.), the diagnostic sensitivity is 96.43% and the diagnostic specificity is 100% During this long fight with COVID-19, Getein Biotech Inc. continuously focuses on the pandemic situation and contributes itself to the prevention and control of this public crisis, so as to promptly support the resumption of the global work & production as well as the early return of people’s normal life. For any needs, please email us via sales@getein.com.cn
    View More
  • Getein Moments at Medlab Middle East 2022
    27

    /Jan 2022

    Getein Moments at Medlab Middle East 2022
    From Jan. 24th to 27th, Medlab Middle East 2022 was held in Dubai World Trade Center. At the exhibition, Getein displayed its fully automatic CLIA POCT analyzer MAGICL 6000 and comprehensive testing solutions for COVID-19, showcasing its latest innovations and products to international friends. As the largest laboratory exhibition in the MENA region, Medlab Middle East continuously attracts a host of industry leaders and influencers to attend. The theme for this year Medlab is "Connect with innovation that's changing the face of diagnostics". This four-day event, bringing together over 400 exhibitors from 38 countries, offered a platform for cutting-edge technology and innovations designed to tackle the most urgent diagnostics challenges under the COVID-19 pandemic. In Getein booth, many attendees showed great interest in MAGICL 6000, a fully automatic CLIA POCT platform, which debuted at Medlab Middle East. They communicated the applications of MAGICL 6000 with Getein workers and gave good evaluations of its compact size, delicate design, very easy operation, adequate test items and its multiple featured functions. The displayed Getein comprehensive testing solutions for COVID-19 also attracted many attendees to inquire and discuss. For the long-lasting tough pandemic, Getein is dedicated to tackling the pressing diagnostics challenges. By now, Getein has launched COVID-19 antigen self-test solution, antigen professional test solution, neutralizing antibody test solution, COVID-19 nucleic acid test solution, etc. As a leading brand of POCT, Getein will keep on fighting against COVID-19 with our latest technology and innovation. At Medlab Middle East 2022, Getein’s participation let many industry friends and medical workers from different countries have a deeper understanding of its innovative products and overall solutions. The exhibition will come to an end soon, but the innovation will not stop. Getein has always adhered to its mission of "Pursue Excellence, Deliver Health", keeping the health and well-being of patients in mind. In the future, Getein will continue to serve the global healthcare and benefit more people around the world! Click the video below to watch the review of Getein moments at Medlab Middle East 2022!
    View More
  • Getein Biotech is Expecting to See You at Medlab Middle East 2022
    21

    /Jan 2022

    Getein Biotech is Expecting to See You at Medlab Middle East 2022
    Medlab Middle East is where you could view the latest trends of the medical laboratory industry. At the exhibition, you could discover innovative products, trending technology, and more at the upcoming 2022 edition, which will be held 24-27 Jan. 2022 in Dubai World Trade Center. This year, you could meet Getein Biotech at the exhibition! We are really expecting to see you there! Where to find us? Stand Z4. G40! We are excited to meet you at Getein booth and introduce you our latest products and COVID-19 testing solutions. Check the following to have a glance at our products that will show in our booth. MAGICL 6000 Chemiluminescence Immunoassay Analyzer MAGICL 6000 Chemiluminescence Immunoassay Analyzer is an automatic CLIA POCT platform with a throughput of 150 T/H, supporting whole blood test with HCT function. The good-looking and flexible CLIA POCT analyzer MAGICL 6000 can't wait to meet you! Getein COVID-19 Testing Solutions Getein COVID-19 testing solutions will also present at the exhibition, including the antigen self-test, antigen professional test, neutralizing antibody test, IgG/IgM antibody test, nucleic acid test, and clinical management indicators. The applications range from screening, diagnosis, clinical management of COVID-19 to the vaccination effect testing . Lastly, please check the video here to know more about us at Medlab Middle East 2022. We are waiting for you!
    View More
  • Official Announcement of Getein Animal Medical Technology Co., LTD
    01

    /Jan 2022

    Official Announcement of Getein Animal Medical Technology Co., LTD
    Official Announcement! Right at the beginning of 2022, Getein Biotech officially announced its entry into the veterinary diagnostic market. Its wholly-owned subsidiary, Getein Animal Medical Technology Co., LTD (Getein Animal), released its new products on January 1, 2022, looking for partners in the veterinary diagnostic field. Getein Animal Medical Technology Co., LTD is a wholly-owned subsidiary of Getein Biotech, Inc. (SSE stock code: 603387), established in December 2021, focusing on the IVD instruments and reagents solutions for pets. It is committed to sticking to high-quality, fast, accurate and highly sensitive diagnostic technologies, letting human’s four-leg friends enjoy the equally high-quality healthcare as human. Founded in 2002, Getein Biotech, Inc. is a medical and healthcare company integrating independent innovation and R&D, large-scale production and specialized marketing, with numerous subsidiaries and offices in China and overseas. The company was listed on the main board of Shanghai Stock Exchange in July 2017, and is the first domestic company in the field of POCT listed on the main board. The company has a professional R&D center for diagnostic products and has established 10 technical platforms including point-of-care testing, chemiluminescence immunoassay, clinical chemistry, hematology, molecular diagnostics, etc. Getein has rich experience in market and distribution management, providing perfect and professional services for our distributors and customers. Backed by Getein Biotech, Inc. and some other partner companies’ R&D and manufacture systems, Getein Animal currently possesses five major technology platforms in the pet diagnostic business, including hematology, dry clinical chemistry, colloidal gold, immunofluorescence and molecular diagnostics. Facing the current situation and needs of pet medical market, we are dedicated to accelerating the development of the pet diagnostic industry. With the aging process of the Chinese society, our family structure is changing with increasing empty nesters and DINK families. More and more families choose to keep a pet and treat their pets as family members due to their strong emotional needs. It is expected that the number of pets kept in China will continuously grow at around 10% compound annual growth rate in the coming years. Along with this trend, the importance of pets in the minds of pet owners as well as social attention has also changed qualitatively, largely promoting the upgrade of consumption concepts and pushing the development of the pet economy towards the direction of specialization and refinement. As an important part of pet medical treatment, pet diagnosis requires a higher degree of specialization and is in line with the development direction of human medical testing of simple operation, fast testing, accurate results, high precision and high sensitivity. Getein Biotech and its multiple POCT platforms have 20 years of experience and is well valid...
    View More
  • Getein SARS-CoV-2 Antigen Self-Test Certified by Thailand and Malaysia
    09

    /Dec 2021

    Getein SARS-CoV-2 Antigen Self-Test Certified by Thailand and Malaysia
    Recently, One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) developed and manufactured by Getein Biotech, Inc. has been approved by MDA (Medical Device Authority Malaysia) and TFDA (Food and Drug Administration Thailand) respectively, and is approved to be marketed in both countries for self-testing of COVID-19 infection by the public. Currently, the self-test kits are widely available for purchase at pharmacies and medical institutions in both countries. Certificate of Malaysia MDA Certificate of Thailand FDA Multiple countries Certified, Quality Management System Guaranteed In addition to the certifications in Malaysia and Thailand, Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) also received CE certification as early as July this year for its excellent clinical performance. By now, only 13 biotech companies in China have obtained the CE certification for their COVID-19 antigen self-test products. Besides, Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) has also passed the PEI test in Germany and DHSC 3a verification in UK, and is listed on the import and export white lists of the EU and China. Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) is self-developed and produced by our self-owned factory using our self-produced raw materials, giving us superior quality control power over our product quality compared to other manufacturers in the industry. In addition, our ISO 13485 quality control system, which has been jointly audited by five countries, adds an extra layer of assurance of quality to our products. Easy and Fast Testing Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) is very easy and fast to operate. No testing equipment is required. Individuals could perform the test by collecting nasal swabs themselves. The sampling process is simple and comfortable and the test results can be obtained in just 10-15 min. The convenient operation allows this test to be widely used in many scenarios such as home, school, workplace, dormitory, cruise ship, airport, theater, etc. Lately, Getein Biotech Inc. has improved the previous boxed single antigen test pack to a new soft pack design, saving significantly the shipping space and costs for our clients. The soft pack design comes with multiple languages on the package while keeping the exact same certifications as the boxed version, which allows its legal distribution in multiple markets. A Comprehensive COVID-19 Test Solution Backed by Strong R&D Power In order to respond to the global public health crisis, since the outbreak of the epidemic, Getein Biotech Inc. has organized its R&D team to quickly respond and launch a full range of nucleic acid + antigen + antibody + influenza differential test solutions to meet the needs of COVID-19 detection in different application scenarios, covering the full cycle of COVID-19 infection. At present, the company has more than ten COVID-19 testing products, all of which has obtained CE certifications...
    View More
1 2

A total of 2 pages

Leave A Message
Please leave a message here if your are interested, we will reply to you ASAP.

Home

Products

about

contact